The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 201–300 of 1,007
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
“[22] defend the prevention of Aβ deposition in patients that are in risk of developing AD as a robust test of the amyloid hypothesis.”
BackgroundUddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 124
Schmidt, M. E., Chiao, P., Klein, G., Matthews, D., Thurfjell, L., Cole, P. E., Margolin, R., Landau, S., Foster, N. L., Mason, N. S., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.09.004 · Cited by 125
“[14]).”
Alasmari, F., Alshammari, M. A., Alasmari, A. F., Alanazi, W. A., & Alhazzani, K. (2018) · BioMed Research International · doi:10.1155/2018/3087475 · Cited by 125
“AD is accompanied by the formation of beta-amyloid (Aβ) plaques, neurodegeneration, and neuroinflammation [for review, see [11]].”
BackgroundTau imaging in neurodegenerative diseases
Dani, M., Brooks, D. J., & Edison, P. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3231-2 · Cited by 124
“Recent Aβ imaging studies support the Aβ cascade hypothesis to some extent [14], but it is now recognised that Aβ deposition alone cannot explain AD progression and pathogenesis.”
ResultAlzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
“Thus, APP and PSEN have been the central frameworks of AD research, leading to two "gene-centric" hypotheses of AD etiology: the amyloid hypothesis[20][57][58] and the presenilin hypothesis[59][60].”
BackgroundChen, H., Xiao, M., He, J., Zhang, Y., Liang, Y., Liu, H., & Zhang, Z. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00967 · Cited by 131
Walton, J. R. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132204 · Cited by 123
“On the other hand, pharmaceutical companies were reported to be withdrawing funding for A human vaccination trials with at least one research group having concluded that the science of the amyloid cascade hypothesis needed more critical examination [212].”
BackgroundThe Dependence of Amyloid‐β Dynamics on Protein Force Fields and Water Models
Somavarapu, A. K., & Kepp, K. P. (2015) · ChemPhysChem · doi:10.1002/cphc.201500415 · Cited by 124
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Kim, D., Kwon, H. J., & Hyeon, T. (2019) · Advanced Materials · doi:10.1002/adma.201807965 · Cited by 121
Sorting receptor SORLA – a trafficking path to avoid Alzheimer disease
Willnow, T. E., & Andersen, O. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.125393 · Cited by 121
J-ADNI Study Group, Yamane, T., Ishii, K., Sakata, M., Ikari, Y., Nishio, T., Ishii, K., Kato, T., Ito, K., & Senda, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3591-2 · Cited by 125
Nutritional prevention of cognitive decline and dementia.
Dominguez, L. J., & Barbagallo, M. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i2.7401 · Cited by 166
“Amyloid-beta accretion induces neuroinflammation, which consecutively produces more amyloid-beta, propagating the injury (35).”
BackgroundTeixeira, J. P., de Castro, A. A., Soares, F. V., da Cunha, E. F. F., & Ramalho, T. C. (2019) · Molecules · doi:10.3390/molecules24234410 · Cited by 121
“It is important to mention that the pathological mechanisms of AD are still unclear [21].”
BackgroundLearning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
De Strooper, B., & Chávez Gutiérrez, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124309 · Cited by 119
“Amyloid plaques and tau tangles form a defining characteristic of sporadic AD, in which aging, vascular problems, inflammation, and genetic and environmental factors likely interact with the toxic effects of these peptides to cause neurodegeneration (1).”
Self-citationTherapeutic approaches to modulating Notch signaling: Current challenges and future prospects
Groth, C., & Fortini, M. E. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.016 · Cited by 121
n-3 LCPUFA improves cognition: The young, the old and the sick
Joffre, C., Nadjar, A., Lebbadi, M., Calon, F., & Layé, S. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.05.001 · Cited by 137
“Although this model relies on a direct neurotoxic effect of Aβ monomers, which is of debatable AD relevance [138,139], the data generated clearly support improving effects of dietary DHA on memory and learning ability [140–143].”
ResultFonseca, A. C. R. G., Ferreiro, E. B., Oliveira, C. R., Cardoso, S. M., & Pereira, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.007 · Cited by 122
“Introduction According to the ‘Amyloid Cascade Hypothesis’, the accumulation of amyloid-beta (Aβ) in brain parenchyma is responsible for the neurodegenerative process in Alzheimer’s disease (AD) [1].”
BackgroundQuiroz, Y. T., Schultz, A. P., Chen, K., Protas, H. D., Brickhouse, M., Fleisher, A. S., Langbaum, J. B., Thiyyagura, P., Fagan, A. M., Shah, A. R., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1099 · Cited by 120
Hu, Y., Kirmess, K. M., Meyer, M. R., Rabinovici, G. D., Gatsonis, C., Siegel, B. A., Whitmer, R. A., Apgar, C., Hanna, L., Kanekiyo, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8392 · Cited by 120
Wang, Y., Wang, Q., Zhang, T., Liu, Y.-H., Yao, X., Zeng, F., Li, J., Zhou, F.-Y., Wang, L., Yan, J.-C., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9826-1 · Cited by 132
Amin, F. U., Hoshiar, A. K., Do, T. D., Noh, Y., Shah, S. A., Khan, M. S., Yoon, J., & Kim, M. O. (2017) · Nanoscale · doi:10.1039/c7nr00772h · Cited by 118
Kim, H. Y., Kim, H. V., Jo, S., Lee, C. J., Choi, S. Y., Kim, D. J., & Kim, Y. (2015) · Nature Communications · doi:10.1038/ncomms9997 · Cited by 117
Jalili‐Baleh, L., Babaei, E., Abdpour, S., Bukhari, S. N. A., Foroumadi, A., Ramazani, A., Sharifzadeh, M. S., Abdollahi, M. R., & Khoobi, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.004 · Cited by 126
Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer’s Disease
Vingtdeux, V., Sergeant, N., & Buée, L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00229 · Cited by 116
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
“…the straightforward predictions from the major theory of the field, i.e., the amyloid cascade hypothesis (Hardy & Selkoe 2002), did not translate into the clinic as easily as researchers had hoped (for a critical appraisal of the amyloid hypothesis, see Benilova et al. 2012, Karran et al. 2011).”
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 114
Potapov, A., Yau, W., Ghirlando, R., Thurber, K. R., & Tycko, R. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04843 · Cited by 125
NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?
Sorce, S., Stocker, R., Seredenina, T., Holmdahl, R., Aguzzi, A., Chio, A., Depaulis, A., Heitz, F., Olofsson, P., Olsson, T., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.006 · Cited by 115
Targeting Renin–Angiotensin System Against Alzheimer’s Disease
Gebre, A. K., Altaye, B. M., Atey, T. M., Tuem, K. B., & Berhe, D. F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00440 · Cited by 116
“ACE reduces amyloid β peptides the main risk factor for the development and progression of AD (Karran et al., 2011) (Table 1).”
BackgroundVitamin E and Alzheimer’s disease: what do we know so far?
Browne, D., McGuinness, B., Woodside, J. V., & McKay, G. J. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s186760 · Cited by 114
“…theory, several concerns have questioned the assumption of direct causality, including the failure of therapeutic interventions targeting the amyloid pathway to provide clinical bene fi t 21 and an extensive body of evidence suggests the pathological processes of AD are complex and multifactorial.”
Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y.-J., Willis, B. A., Gueorguieva, I., Lo, A. C., Fleisher, A. S., Dage, J. L., Ardayfio, P., et al. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.56 · Cited by 115
“Cough 0 (0) 0 (0) 0 (0) 0 (0) 1 [1] (10.”
InfluentialShinohara, M., Fujioka, S., Murray, M. E., Wojtas, A., Baker, M., Rovelet-Lecrux, A., Rademakers, R., Das, P., Parisi, J. E., Graff-Radford, N. R., et al. (2014) · Brain · doi:10.1093/brain/awu046 · Cited by 115
“Although an increase in production of amyloid-b42 or increased ratio of amyloid-b42 to amyloid-b40 is clearly implicated in the pathogenesis of familial Alzheimer’s disease (Karran et al., 2011), it remains unknown how amyloid-b metabolism is disturbed and thus involved in sporadic Alzheimer’s disease.”
InfluentialReview of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds
Feng, Y., & Bounda, G. (2015) · Pharmacognosy Research · doi:10.4103/0974-8490.157957 · Cited by 129
“[109,110] In order to avoid location bias, as nearly all these studies are conducted in China, other countries are also encouraged further to pursue CHM clinical studies in the treatment of sleep disorders.[112]”
BackgroundThe unfolded protein response in Alzheimer’s disease
Cornejo, V. H., & Hetz, C. A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0373-9 · Cited by 129
“Gradual changes in the steady-state levels of Aβ peptide in the brain are thought to initiate the amyloid cascade [11, 15].”
BackgroundSgourakis, N. G., Yau, W., & Qiang, W. (2014) · Structure · doi:10.1016/j.str.2014.10.022 · Cited by 121
Nabers, A., Ollesch, J., Schartner, J., Kötting, C., Genius, J., Hafermann, H., Klafki, H., Gerwert, K., & Wiltfang, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04286 · Cited by 115
Obstructive sleep apnoea and Alzheimer’s disease: In search of shared pathomechanisms
Polsek, D., Gildeh, N., Cash, D., Winsky-Sommerer, R., Williams, S. C. R., Turkheimer, F., Leschziner, G. D., Morrell, M. J., & Rosenzweig, I. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.12.004 · Cited by 113
“(Karran et al., 2011) The hypothesis posits that the imbalance between the production and clearance of amyloid-β (Aβ) peptide in the brain is the initiating and central event in AD pathology, ultimately leading to neurodegeneration and dementia.”
BackgroundTau deposition patterns are associated with functional connectivity in primary tauopathies
Franzmeier, N., Brendel, M., Beyer, L., Slemann, L., Kovacs, G. G., Arzberger, T., Kurz, C., Respondek, G., Lukic, M. J., Biel, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28896-3 · Cited by 114
Circadian Rhythm and Alzheimer’s Disease
Homolak, J., Mudrovčić, M., Vukić, B., & Toljan, K. (2018) · Medical Sciences · doi:10.3390/medsci6030052 · Cited by 138
“The amyloid cascade hypothesis, the most influential hypothesis favored both by academic research and pharmaceutical industry for the past 20 years, advocates that deposition of amyloid-β peptides in the brain parenchyma is the central event that drives Alzheimer’s disease pathology [14].”
BackgroundChoroidal Neovascularization: Mechanisms of Endothelial Dysfunction
Yeo, N. J. Y., Chan, E. J. J., & Cheung, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01363 · Cited by 123
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
Kanwar, J., Sriramoju, & Kanwar (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30919 · Cited by 108
“neuroanatomical location reflects the extent of neuronal damage, triggering of tau protein, and dementia.(27) Other proteins”
BackgroundAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Verkhratsky, A., Marutle, A., Rodríguez-Arellano, J. J., & Nordberg, A. (2015) · The Neuroscientist · doi:10.1177/1073858414547132 · Cited by 95
A critical analysis of the ‘amyloid cascade hypothesis’
A. Armstrong, R. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45562 · Cited by 110
“As a result, numerous studies of AD pathogenesis have been carried out [6,8] and potential treatments proposed and tested based on the ACH [69,113].”
BackgroundAlzheimer's in 3D culture: Challenges and perspectives
D'Avanzo, C., Aronson, J., Kim, Y. H., Choi, S. H., Tanzi, R. E., & Kim, D. Y. (2015) · BioEssays · doi:10.1002/bies.201500063 · Cited by 111
“With strong experimental support from many studies, this hypothesis is the framework for most current clinical trials for potential AD therapies [7].”
BackgroundGrundman, M., Morgan, R., Lickliter, J. D., Schneider, L. S., DeKosky, S., Izzo, N. J., Guttendorf, R., Higgin, M., Pribyl, J., Mozzoni, K., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.001 · Cited by 96
“Symptomatic treatments that are available for AD only transiently slow cognitive decline [8], and prior clinical investigation of small molecule inhibitors and modulators of the g-secretase and b-secretase enzymes that cut Ab from its full-length precursor have not shown significant clinical efficacy [9–11].”
BackgroundPalma-Florez, S., López-Canosa, A., Moralez-Zavala, F., Castaño, Ó., Kogan, M. J., Samitier, J., Lagunas, A., & Mir, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01798-2 · Cited by 124
“Since AD is characterized by neuronal death associated partly with extracellular accumulation of beta amyloid (Aβ) plaques, several therapeutics agents are focused on altering the Aβ fibrillation process and promote their clearance [29, 30], although none have been fully successful.”
BackgroundExtracellular Vesicles in Brain Tumors and Neurodegenerative Diseases
Ciregia, F., Urbani, A., & Palmisano, G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00276 · Cited by 110
“…abnormally folded amyloid β (Aβ) and tau proteins (hyper-phosphorylated tau; p-tau) in amyloid plaques and neuronal tangles, respectively, are causally connected to the typical neurodegenerative process in patients’ brains (Karran et al., 2011; De Strooper and Karran, 2016; Scheltens et al., 2016).”
BackgroundFamilial Alzheimer’s Disease Mutations in Presenilin Generate Amyloidogenic Aβ Peptide Seeds
Veugelen, S., Saito, T., Saido, T. C., Chávez‐Gutiérrez, L., & Strooper, B. D. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.010 · Cited by 130
Self-citationBelloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110
Pozdnyakov, N., Murrey, H. E., Crump, C. J., Pettersson, M., Ballard, T. E., am Ende, C. W., Ahn, K., Li, Y.-M., Bales, K. R., & Johnson, D. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398602 · Cited by 107
“Abnormal accumulation of -amyloid (A )(4) peptides in brain regions critical for learning and memory has been implicated as causative for Alzheimer disease (AD) progression (1, 2).”
BackgroundDubois, B., López-Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01169-x · Cited by 107
“The primary neuropathologic features of AD are the presence of extracellular β-amyloid (Aβ) and intracellular hyperphosphorylated tau deposits, which are linked through the amyloid cascade hypothesis [2].”
BackgroundThe Effect of Curcumin on the Stability of Aβ Dimers
Zhao, L. N., Chiu, S.-W., Benoit, J., Chew, L. Y., & Mu, Y. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp3034209 · Cited by 119
Menopause, obesity and inflammation: interactive risk factors for Alzheimer’s disease
Christensen, A., & Pike, C. J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00130 · Cited by 108
“Interestingly, increased proinflammatory factors can result in greater amyloid precursor protein production, leading to even more Aβ release and creating a vicious cycle that further promotes AD pathology (Karran et al., 2011).”
BackgroundKyrtsos, C. R., & Baras, J. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139574 · Cited by 108
Tosun, D., Landau, S., Aisen, P. S., Petersen, R. C., Mintun, M., Jagust, W., Weiner, M. W., & Initiative, F. T. A. D. N. (2017) · Brain · doi:10.1093/brain/awx046 · Cited by 107
“According to the amyloid-b hypothesis (Hardy and Selkoe, 2002; Karran et al., 2011), the accumulation of amyloid-b leads to downstream events including accumulation of tau tangles, neurodegeneration, cognitive decline and dementia.”
BackgroundInfluentialNogueras-Ortiz, C. J., Mahairaki, V., Delgado-Peraza, F., Das, D., Avgerinos, K., Eren, E., Hentschel, M., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 106
“Although the amyloid hypothesis has been the predominant theory for AD pathogenesis (60), efforts aimed at translating it into effective therapies have failed, raising renewed interest in alternative therapeutic targets, particularly”
BackgroundDysregulation of TrkB Receptors and BDNF Function by Amyloid-β Peptide is Mediated by Calpain
Jerónimo-Santos, A., Vaz, S. H., Parreira, S., Rapaz-Lérias, S., Caetano, A. P., Buée-Scherrer, V., Castrén, E., Valente, C. A., Blum, D., Sebastião, A. M., et al. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhu105 · Cited by 107
“Nevertheless, it is estimated that Aβ42 is present in ISF at a concentration range of nanomolar (see Karran et al. 2011).”
BackgroundTau Positron Emission Tomography (PET) Imaging: Past, Present, and Future
Ariza, M., Kolb, H. C., Moechars, D., Rombouts, F., & Andrés, J. I. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5017544 · Cited by 107
Barros-Viegas, A. T., Carmona, V., Ferreiro, E., Guedes, J., Cardoso, A. M., Cunha, P., Pereira de Almeida, L., Resende de Oliveira, C., Pedro de Magalhães, J., Peça, J., et al. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2020.01.010 · Cited by 106
Novak, G., Streffer, J. R., Timmers, M., Henley, D., Brashear, H. R., Bogert, J., Russu, A., Janssens, L., Tesseur, I., Tritsmans, L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00614-5 · Cited by 107
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
“The slow rate of A deposition emphasizes the existence of a large temporal window for modifying A accumulation and supports the mounting consensus that anti-A therapy might need to be provided early in the disease course, presumably at the asymptomatic stages, to be operative and to effectively halt the development of…”
Irwin, R. W., & Brinton, R. D. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.08.004 · Cited by 106
Zhang, J., Guo, Y., Wang, Y., Song, L., Zhang, R., & Du, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.025 · Cited by 110
“The pathogenesis of AD mainly includes the abnormal accumulation of β-amyloid proteins (Aβ) and phosphorylated Tau, which form senile plaques (SP) and neurofibrillary tangles (NFT) in the brain respectively [3].”
BackgroundSkaat, H., Chen, R., Grinberg, I., & Margel, S. (2012) · Biomacromolecules · doi:10.1021/bm3011177 · Cited by 104
Application of Free Energy Perturbation for the Design of BACE1 Inhibitors
Ciordia, M., Pérez-Benito, L., Delgado, F., Trabanco, A. A., & Tresadern, G. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00220 · Cited by 104
Swahn, B.-M., Kolmodin, K., Karlström, S., von Berg, S., Söderman, P., Holenz, J., Berg, S., Lindström, J., Sundström, M., Turek, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009025 · Cited by 101
Coronel, R., Bernabeu-Zornoza, A., Palmer, C., Moreno, M. D. M. M., Zambrano, A., Cano, E., & Liste, I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0914-2 · Cited by 117
“caused by autosomal dominant mutations in PSEN1, PSEN2 and APP which are essential in generating Aβ peptides [87, 88].”
Pasquier, F., Sadowsky, C., Holstein, A., Leterme, G. L. P., Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150376 · Cited by 102
“Genetic and pathologic evidence support a role for aberrant production or clearance of A in the genesis of AD [1, 3, 4].”
BackgroundCong, L., Dong, X., Wang, Y., Deng, Y., Li, B., & Dai, R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.039 · Cited by 106
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno-Gonzalez, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 102
“Then, new insights into AD pathophysiology are driving the development of drugs towards novel therapeutic targets [34,35].”
Sillerud, L. O., Solberg, N. O., Chamberlain, R., Orlando, R. A., Heidrich, J. E., Brown, D. C., Brady, C. I., Vander Jagt, T. A., Garwood, M., & Vander Jagt, D. L. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121171 · Cited by 103
Iulita, M. F., Allard, S., Richter, L., Munter, L.-M., Ducatenzeiler, A., Weise, C., Do Carmo, S., Klein, W. L., Multhaup, G., & Cuello, A. C. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-61 · Cited by 103
“However, it is widely accepted that before the overt deposition of amyloid plaques and neurofibrillary tangles, the accumulation of amyloid-β (Aβ) peptides is one of the first steps in the series of pathogenic changes that lead to neurodegeneration and dementia [5,6].”
BackgroundLi, Y., Xu, D., Ho, S.-L., Li, H.-W., Yang, R., & Wong, M. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.047 · Cited by 102
Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 102
Zhang, C., Zheng, X., Xu, W., Shao, X., Liu, Q., Zhang, Z., & Zhang, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.050 · Cited by 106
Yang, H., Sun, Z., & Chen, S. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-21 · Cited by 124
“worsening of the symptom is related with its effect on Notch signaling [6].”
BackgroundTransient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Hubin, E., van Nuland, N. A. J., Broersen, K., & Pauwels, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1634-z · Cited by 104
“The current amyloid cascade hypothesis suggests that AD-related synapto- and neurotoxicity might be mediated by soluble Aβ oligomers [17, 18], Abstract The aggregation and deposition of the amyloid-β peptide (Aβ) in the brain has been linked with neuronal death, which progresses in the diagnostic and pathological sign…”
BackgroundPolyphenols Modulate Alzheimer’s Amyloid Beta Aggregation in a Structure-Dependent Manner
Phan, H. T. T., Samarat, K., Takamura, Y., Oussou-Azo, A. F., Nakazono, Y., & Vestergaard, M. C. M. (2019) · Nutrients · doi:10.3390/nu11040756 · Cited by 112
Sun, L., Cho, H.-J., Sen, S., Arango, A. S., Huynh, T. T., Huang, Y., Bandara, N., Rogers, B. E., Tajkhorshid, E., & Mirica, L. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05470 · Cited by 98
“…formation of extracellular amyloid plaques containing the amyloid β (A β ) peptide is one of the pathological hallmarks of the brains of AD patients, 4,5 and this led to the amyloid-cascade hypothesis that states the amyloid plaque formation initiates cellular events that lead to neurodegeneration.”
Oridonin Attenuates Aβ1–42-Induced Neuroinflammation and Inhibits NF-κB Pathway
Wang, S., Yang, H., Yu, L., Jin, J., Qian, L., Zhao, H., Xu, Y., & Zhu, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104745 · Cited by 100
“plaques in the brain have been thought as key events during the progression of AD [24].”
BackgroundStamford, A. W., Scott, J. D., Li, S. W., Babu, S., Tadesse, D., Hunter, R., Wu, Y., Misiaszek, J., Cumming, J. N., Gilbert, E. J., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3001165 · Cited by 99
Amylin at the interface between metabolic and neurodegenerative disorders
Lutz, T. A., & Meyer, U. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00216 · Cited by 100
“According to one hypothesis, prolonged hyperglycemia may lead to a higher concentration of pro-amylin within the β-cells (Hou et al., 1999), which in turn may create a core for amylin aggregation and ultimately cause β-cell loss and deposition of extracellular amyloid (Paulsson and Westermark,…”
BackgroundInfluentialHales, C. M., Dammer, E. B., Deng, Q., Duong, D. M., Gearing, M., Troncoso, J. C., Thambisetty, M., Lah, J. J., Shulman, J. M., Levey, A. I., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600057 · Cited by 99
“Alzheimer’s disease (AD) is characterized by extracellular deposition of detergent-insoluble -amyloid (A ) as senile plaques, as well as intracellular accumulation of neurofibrillary tangles (NFTs) composed of aggregated tau [3, 4].”
BackgroundInfluentialHickey, J. L., Lim, S., Hayne, D. J., Paterson, B. M., White, J. M., Villemagne, V. L., Roselt, P. D., Binns, D., Cullinane, C. M., Jeffery, C. M., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4057807 · Cited by 116
Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
“These results are in line with the concept that Ab may be a driving pathological force early in the disease process [97], whereas other neurodegenerative phenomena, such as tau tangles, better relate to cognitive deterioration at later stages [98,99].”
ResultAlzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities
Haque, R. U., & Levey, A. I. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912954116 · Cited by 103
Deep tissue multi-photon imaging using adaptive optics with direct focus sensing and shaping
Qin, Z., She, Z., Chen, C., Wu, W., Lau, J. K. Y., Ip, N. Y., & Qu, J. Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01343-w · Cited by 123
Amyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
Brase, L., You, S.-F., D’Oliveira Albanus, R., Del-Aguila, J. L., Dai, Y., Novotny, B. C., Soriano-Tarraga, C., Dykstra, T., Fernandez, M. V., Budde, J. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37437-5 · Cited by 98
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 105
Vitamin D and Alzheimer’s Disease: Neurocognition to Therapeutics
Banerjee, A., Khemka, V. K., Ganguly, A., Roy, D., Ganguly, U., & Chakrabarti, S. (2015) · International Journal of Alzheimer's Disease · doi:10.1155/2015/192747 · Cited by 97
“in the amyloid metabolic cascade constitute an important hypothesis in AD, though none of the theories alone is sufficient to decipher the biochemical and pathological complexities that result in disease progression [19].”
BackgroundZempel, H., & Mandelkow, E.-M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0064-1 · Cited by 96
“AD-like pathological changes of Tau, we exposed primary neurons to a pre-aggregation form of Aβ (oligomeric Aβ), which is thought to be the toxic trigger in AD [3, 24, 35].”
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
“The amyloid cascade hypothesis is one of the signaling pathways that has been thoroughly investigated concerning AD [81].”
BackgroundKim, D. K., Park, J., Han, D., Yang, J., Kim, A., Woo, J., Kim, Y., & Mook-Jung, I. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0234-4 · Cited by 95
“The amyloid cascade hypothesis claims that Aβ is the initial trigger for further pathological changes, including tau hyper-phosphorylation and NFT formation, which accelerate AD progression [51].”
BackgroundZhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99
Nuclear signalling by membrane protein intracellular domains: The AICD enigma
Beckett, C., Nalivaeva, N. N., Belyaev, N. D., & Turner, A. J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.007 · Cited by 115
On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis
Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.10.001 · Cited by 122
“…mcastello@llu.edu (M.A. Castello), ssoriano@llu.edu (S. Soriano). perspective have had negligible effect on cognitive functioning and in some cases have even accelerated disease progression (Aisen et al., 2013; Benilova et al., 2012; Karran et al., 2011; Mullard, 2012; Sperling et al., 2011).”
Background
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.